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Loop-mediated isothermal amplification (LAMP) is a nucleic acid method which has
been used to identify mycobacteria including Mycobacterium tuberculosis in clinical
microbiology laboratory and point of care settings. Previously published LAMP protocols
for detection of mycobacterial species used conventional specific primer and targeted the
16S rRNA, gyrB, and insertion sequence genes. We developed and evaluated a LAMP
assay targeting a mycobacterial rpoB gene conserved sequence and incorporating
degenerate primers. This assay allowed consensus detection of mycobacterial species
from pure culture, clinical respiratory tract samples, and mycobacteria growth indicator
tube (MGIT) liquid-based culture medium. A panel of twenty mycobacterial species
were successfully detected at detection thresholds of 102 CFU/mL and 103 CFU/mL
when respectively performed on pure culture suspension or sputum and MGIT
broth. The inclusion of degenerate bases in LAMP primers increased the diversity of
mycobacterial species identified by the assay without negatively affecting analytical
sensitivity. LAMP-based consensus detection of multiple pathogens can be achieved
with degenerate primers therefore allowing the design of rapid multi-disease screening
assays. Despite high analytical sensitivity, species specificity and the advantageous
operational characteristics of LAMP over PCR, challenges such as potential ambiguity
in visual interpretation of results and occasional non-specific amplification precludes
the implementation of novel LAMP assay in routine diagnostics both in centralized and
point-of-care laboratory.
Keywords: non-tuberculosis mycobacteria,Mycobacterium tuberculosis, loop mediated isothermal amplification,
nuclear acid amplification assay, pulmonary infection
INTRODUCTION
Tuberculosis remains the bacterial disease with the highest mortality worldwide with 1.3 million
deaths in 2016 (1). Although less frequent, a growing diversity of non-tuberculous mycobacteria
(NTM) are increasingly recognized as lung pathogens. Longevity of immunocompromised
populations, chronic pulmonary diseases and increased invasiveness of care and associated
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nosocomial incidents are factors contributing to this changing
epidemiology (2–4). NTM pulmonary infections typically
present as non-specific respiratory clinical syndromes in
vulnerable populations and require long term and potentially
toxic multi-drug therapies which are not routinely prescribed
empirically. Rapid diagnosis of mycobacterial disease relies on
poorly sensitive and specific staining or targeted nuclear acid
amplification tests (NAATs) (5–7). In routine microbiology
diagnostic laboratories, species specific mycobacterial NAATs are
performed on selected clinical samples with high positive pre-
test probability and are therefore tributary of accurate clinical
suspicion and optimal communication between clinicians and
laboratories. These assays are generally highly sensitive and
specific but poorly adapted for rapid screening of pulmonary
NTM infections in the face of non-specific respiratory clinical
syndromes.
Loop-mediated isothermal amplification (LAMP) is an
isothermal NAAT which has been developed and optimized
for microbiology diagnostics (8, 9). Through autocycling strand
displacement DNA synthesis by a Bst DNA polymerase, LAMP
technology isothermally synthesizes high amounts of variable
size DNA amplification products. LAMP technology has the
following advantages: (i) it is highly specific due to a set of four
to six primers recognizing six to eight specific DNA regions; (ii)
it is independent of thermocycling therefore reducing hands-on
and total turnaround time; (iii) it produces large quantities of
DNA allowing visual interpretation of results using fluorescent
intercalant agents or pH indicators; (iv) it has higher tolerance
to inhibitors and is therefore compatible with simpler and faster
extraction protocols. These characteristics are well suited for
point-of-care diagnosis and LAMP assays have previously been
evaluated for diagnosis of mycobacterial and other infectious
diseases in this setting (10). Based on these theoretical advantages
over standard polymerase chain reaction (PCR)-based assays,
several LAMP assays were developed for the rapid detection
of mycobacteria in clinical samples. Yet these assays have been
limited to the detection of specific mycobacterial species by
targeting the 16S rRNA, gyrB, and insertion sequence genes
(11–13).
We previously introduced the rpoB gene as a suitable
molecular target for the detection and identification of
mycobacteria (14). To increase the spectrum of available
tests for the rapid diagnosis of pulmonary mycobacterioses at
point-of-care level, we here designed and evaluated a LAMP
assay incorporating degenerate rpoB gene LAMP primers for
consensus detection of mycobacterial species from pure culture,
clinical respiratory tract samples and mycobacteria growth
indicator tube (MGIT) liquid-based culture medium. This is the
first reported LAMP assay to use degenerate primers to achieve
consensus detection of multiple pathogens.
MATERIALS AND METHODS
LAMP Primers Design
Whole genome reference sequences including those of the
thirteen mycobacterial species and subspecies most frequently
recovered from respiratory samples in the Institut Hospitalier
Universitaire (IHU) Méditerranée Infection microbiology
laboratory were obtained from GenBank database (Table 1).
rpoB gene sequences were extracted and aligned using the
Mycobacterium tuberculosis H37Rv genome as template
(GenBank accession no AL123456.3). Hypervariable rpoB
regions routinely sequenced for mycobacterial identification
to the species level were not considered for the primer design
analysis because of higher inter species genetic variability
(14, 15). Rifampin resistance defining regions (RRDRs) known
to contain single nucleotide polymorphism (SNP) responsible for
drug resistance in M. tuberculosis were also excluded (Figure 1)
(16). Inter-species rpoB gene highly conserved regions were
analyzed using PrimerExplorer V5 software (Fujitsu, Tokyo
Japan). Mutually exclusive sets of forward outer primer F3,
backward outward primer B3c, forward inner primer FIP (F2-
F1c), and backward inner primer BIP (B2c-B1) were identified.
Inter-species nucleotide variability in F1c/B1 5′-terminal, F2/B2c
3′-terminal, and F3/B3c 3′-terminal sites was avoided to ensure
optimal stringency in determinant primer annealing sites.
When unavoidable such variability was tolerated in the F3/B3c
5′-terminal, F2/B2c 5′-terminal, F1c/B1 3′-terminal, and inner
regions (8). Previously described loop primers and FIP/BIP
primer spacers were not used (9). Individual primers specificity
was assessed in silico using NCBI basic local alignment search
tool (BLAST) against human and other bacterial, viral, or fungal
DNA sequences. F1c/B1 and F2/B2c primer sequences were
analyzed both independently and as a continuous fragment.
Selected sets of LAMP primers were then tested on 10-fold serial
dilutions ofM. bovis BCG andM. avium subsp. avium DNA and
the single primer set with highest analytic sensitivity was used
for comprehensive assay performance analysis.
Study Samples
Twenty recognized mycobacterial pulmonary pathogens
comprising a combination of reference strains and clinical
isolates from IHU referencemycobacteria laboratory, five aerobic
actinomycetes rarely encountered in respiratory infections and
six bacteria frequently responsible for community acquired
and nosocomial pneumonia were used to evaluate LAMP assay
performance (Table 1). Mycobacterial identification to the
species level was confirmed using mass spectrometry and rpoB
gene sequencing as per previously published protocols (14, 17).
Bacterial pure cultures were obtained from Midlebrook 7H10,
Colombia + 5% sheep blood or Buffered Charcoal Yeast Extract
solid culture media per growth requirements. Standardized
bacterial suspensions were prepared at 104 CFU/mL, reported to
be the detection limit of smear microscopy for M. tuberculosis
(18). Ten-fold serial dilutions were also prepared to further assess
LAMP assay analytic sensitivity. Sputum from healthy volunteer
subjects andMGIT liquid culture media (Becton Dickinson, New
Jersey, United States) were spiked with standardized bacterial
concentrations to obtain the same bacterial inoculums.
DNA Extraction
Bacterial DNA was extracted from two mL of a pure
culture suspension, twomL of supernatant from previously
homogenized and centrifuged sputum and two mL of pellet from
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FIGURE 1 | Figure adapted from Adékambi et al. (14). Representation of the mycobacterial rpoB gene regions inter-species variability expressed as number of single
nucleotide polymorphism per 60 bp segments. RRDR, Rifampin resistance defining region; LAMP TB-NTMs, target sequence of the LAMP assay here presented;
Pan-mycobacteria, target sequence for mycobacterial identification as described by Kim et al. (15); Rapid Growers, target sequence for rapidly growing mycobacteria
identification as described by Adékambi et al. (14). Nucleotides positions with reference to M. tuberculosis H37Rv rpoB gene (GenBank accession no AL123456.3).
previously centrifuged MGIT culture medium bottle samples.
After incubation in 200 uL G2TM buffer (Quiagen, Hilden,
Germany) and proteinase K for 10min, study samples were
lyzed using FastprepTM bead-beating benchtop homogenizer
(MP Biomedical, California, United States) and heated to 70◦C
for 30min. Extraction process was completed using EZ1TM
automated DNA kit (Quiagen, Hilden, Germany).
LAMP Reaction and Amplification
Products Detection
LAMP reaction was performed using commercially available
WarmStartTM LAMP Kit (DNA and RNA) (New England
Biolabs, MA, USA). Used reaction mix was as follows: 12.5 uL
WarmStartTM LampMaster mix containing a Bst 2.0 polymerase
(8,000 U/mL), 0.5 uL fluorescent dye, 1 uL target DNA, 1 uL
pure DNA sample, 8.5 uL high quality PCR H2O, and 2.5 uL
primer mix containing 1.6 uM FIP/BIP, 0.2 uM F3/B3, and
0.4 uM LoopF/B for a total reaction volume of 25 uL per
reaction. Isothermal amplification was performed on a CFX96
TouchTM cycler (Bio-Rad, CA, USA). Reaction temperature and
time parameters were initially optimized using M. bovis BCG
and M. avium subsp avium DNA template obtained from pure
culture. A 35-min incubation period at 65◦C followed by a 5-
min polymerase inactivation phase at 85◦C was found to be
optimal. High-quality PCR H2O reagent control and Escherichia
coli ATCC 25922TM negative control were tested in parallel
of every reaction. LAMP amplification products were detected
by both agarose gel electrophoresis and direct fluorescence
visual detection by two independent observers (Figure 2). Five
microliter aliquots of LAMP products were electrophoresed
for 35min in 3% agarose gel and fluorescence detection was
performed using SybeSafeTM DNA staining. Visual detection was
performed under UV lamp and relied on commercially available
fluorescent dye included in LAMP master mix.
RESULTS
Three regions of the M. tuberculosis H37Rv rpoB gene (base
pair positions 481–607, 852–1,072, and 1,970–2,065) were found
to be highly conserved among species (Figure 1). Following
in silico analysis, seven distinct sets of primers were selected
for in vitro testing. Based on superior analytic sensitivity as
demonstrated by consistent amplification of low DNA template
inoculums ofM. bovis BCG (101 CFU/mL) andM. avium subsp.
avium (102 CFU/mL) in 2mL a final set of primers was selected
(Figure 3). F3; 5′-CCGGTCACCGTGCTG-3′, FIP 5′-TGTTGT
CCTTCTCCAGIGTIIGCTGGACCAICGAGCA-3′, B3 5′- GTA
RCGCTTCTCCTTGAAGAAC-3′, BIP 5′-TGGACATCTACC
GCAAGCTGCGTTYTCCARCAGGGTCTGC-3′. This set of
LAMP primers includes a total of seven degenerate bases at
selected unavoidable mutation sites in the B3c 5′-terminal,
F2/B2c 5′-terminal, F1c 3′-terminal, and inner regions. Inter-
species phylogenetic relatedness analysis within the rpoB 112
bps combined primer-targeted regions showed between 0 bp
(M. tuberculosis, M. bovis, M. bovis BCG, M. africanum, and
M. canettii sub-species of the M. tuberculosis complex) and 12
bps (M. kansasii and M. bolletii) variability between species
(Figure 4). In silico analysis revealed aerobic actinomycetes to
be genetically closely related to mycobacterial target species
with Tsukamurella sp. (GeneBank accession No. CP019066.1)
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FIGURE 2 | Agarose gel electrophoresis (A) and direct fluorescence (B) based detection of LAMP amplification products for H2O reagent control (left), Escherichia
coli negative control (middle) and M. tuberculosis H37Rv (right).
FIGURE 3 | M. tuberculosis H37Rv reference strain rpoB target sequence with degenerate LAMP primer annealing sites. The primers are as follows: F3, forward;
B3c, backward; FIP, forward inner (F1c and F2); BIP, backward inner (B2c and B1).
and Streptomyces sp. (GeneBank accession No. CP025407.1),
respectively, sharing 7 and 13 of 112 bps with theM. tuberculosis
H37Rv reference sequence within the LAMP primer annealing
sites.
LAMP positive amplification reactions were successfully
documented using gel electrophoresis and fluorescence direct
visualization after a 35-min incubation. Concordance between
both detection methods was absolute throughout the study.
For all LAMP reactions presented here, reagent controls using
water and negative controls using E. coli were consistently
negative (Figure 2). To confirm the presence of mycobacterial
DNA and rule out non-specific amplification due to primer
auto-amplification which has been recognized as a challenge
in LAMP assays optimization (manufacturer’s communication,
unpublished data), small fragments of amplification products of
M. bovis BCG corresponding to bands with the highest molecular
weight in the gel electrophoresis smear were extracted from
agarose l and sequenced usingMiSeq Next-Generation sequencer
(Illumina, CA, USA). Short DNA fragments corresponding to
LAMP targeted rpoB regions but excluding primer annealing
sites were sequenced therefore confirming true positive
results.
Native LAMP primers successfully amplified DNA extracted
from pure cultures of various mycobacterial species including
all of the M. tuberculosis complex, M. avium complex and
M. kansasii. The inclusion of degenerate nucleotide bases in
the LAMP primer set did not negatively impact detection
threshold but further increased the number of mycobacterial
species detected by the assay to all those included in this study
except for M. bolletii. LAMP primers were shown to be highly
specific for mycobacteria as no nosocomial or community-
acquired pneumonia bacterial pathogens were amplified even
after prolonging the reaction time to 60min. Among selected
aerobic actinomycetes with high similarity of the rpoB target
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FIGURE 4 | Mycobacterial inter-species phylogenetic relatedness analysis
within the consensus degenerate rpoB 112 bps combined primer-targeted
regions.
sequence to that of the included mycobacterial species, only
Tsukamurella sp. and Streptomyces sp. were amplified. When
performed on DNA extracted from spiked sputum and liquid
culture medium the LAMP assay yielded highly comparable
species sensitivity and specificity. Only M. bolletii and M.
massiliense could not be detected from spiked sputum samples.
M. xenopi could not be tested in spiked sputum and MGIT
samples because of insufficient growth. For most species,
detection limit of the LAMP assay was 102 CFU/mL when
performed on pure culture and 103 CFU/mL on sputum and
MGIT broth (Table 1). Total duration of the LAMP assay was
measured to be 90min, including 45min for extraction, 40min
for isothermal amplification, and 5min for visual fluorescence
detection. Required laboratory technician hands on time was
25min.
DISCUSSION
We set up and evaluated the performance of a novel LAMP assay
for consensus detection of mycobacteria from pure culture and
spiked sputum and MGIT liquid medium samples. Previously
published LAMP protocols for detection of mycobacterial species
used conventional specific primer and targeted the 16S rRNA,
gyrB, and insertion sequence genes (11–13). In this study, we
designed the first LAMP assay to target the rpoB gene for
mycobacterial detection. This is also the first description of a
LAMP assay using primers containing degenerate nucleotide
bases. Including degenerate bases in LAMP primers did not
negatively impact analytical sensitivity but successfully increased
the diversity of mycobacterial species detected by the assay.
Mycobacterial inoculums as low as 103 CFU/mL were detected
in sputum and MGIT broth samples after 35min. This detection
threshold is higher than that of pure culture samples on which
positive reactions were documented for inoculums as low as 102
CFU/mL. As described in previous studies, extending LAMP
reaction time might increase the sensitivity of the assay on
sputum and MGIT broth samples but this was not a consistent
finding in our study (11). Extending incubation time did not
result in false positive reactions when testing a panel of non-
mycobacterial respiratory pathogens. As reported in previous
studies, false positive results were only observed with aerobic
actinomycetes Tsukamurella sp. and Streptomyces sp., two species
genetically closely related to mycobacteria (11). This specificity
issue was considered of low clinical relevance as this these
opportunistic microorganisms are rarely encountered in clinical
lung disease. Whereas, previous studies evaluated the correlation
between detection thresholds of LAMP and PCR for specific
mycobacterial species, this was not performed in this study
considering that no such assay exists for every single included
species and that the LAMP assay described here was meant as
pan-mycobacterial screening test.
Like other isothermal NAATS, our assay is rapid and
technically simple to perform and only requires consumables,
a heat block with constant temperature and a UV lamp for
direct visual detection of results. It therefore has potential for
rapid diagnosis of pulmonary mycobacteroses at the point-of-
care. Despite our promising results and the many theoretical
advantages of LAMP over PCR, this assay proved to have several
limitations. Due to the structural complexity of the LAMP
primer sets, accurate in silico tools to predict the incidence
of primers secondary structures or sensitivity and specificity
for target template are lacking. The resulting necessity of trial
and error experimentation is time and resources consuming.
Fluorescence-based visual detection of results can be equivocal
especially in the presence of samples with lower inoculum.
This ambiguity can easily be resolved by confirming results
by gel electrophoresis although this detection method is not
usually available outside the molecular biology laboratory. While
concordance between gel electrophoresis and direct fluorescence
as assessed by two independent observers was absolute in
our study, un-experienced personnel in a point-of care setting
might find the assessment of “low positive” samples challenging.
Previously reported non-specific amplification was observed in
multiple LAMP reactions. Indeed, positive reactions observed
in reagent controls containing H2O and negative controls
containing E. coli regularly occurred therefore invalidating the
whole reaction. This was observed as frequently with specific and
degenerate primers. DNA sequencing of LAMP amplification
product confirmed true amplification of the mycobacterial target
in reactions with adequate reagent (H2O) and specificity (DNA)
controls.
These encountered challenges may explain why despite a
multiplicity of published protocols and recognized medical,
veterinary and environmental applications LAMP technology
has failed to significantly scale-up at any level between point-
of care settings and reference laboratories (19). Of major
concern for routine laboratory services providers in conventional
or point-of care settings are the visual result detection
ambiguities and potential non-specific amplification in any given
LAMP reaction. These may explain the absence of buy-in for
LAMP technology in these contexts facing limited personnel
training, high human resources turnover and the necessity for
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a streamlined sample workflow. Through increased reaction
parameters standardization, automation could help overcoming
some of these challenges as exemplified by the success of the
WHO endorsed closed platform for LAMP-based detection ofM.
tuberculosis (20, 21).
In conclusion, we designed a novel LAMP assay targeting the
mycobacterial rpoB gene and including degenerate primers
for consensus detection of mycobacterial species from
pure culture, sputum and MGIT broth samples. This assay
showed good analytical sensitivity as well as mycobacterial
species coverage and specificity. Despite these results and
the advantages of LAMP over PCR, challenges such as
result interpretation ambiguity and potential non-specific
amplification precludes the routine use of this novel LAMP assay
both in centralized and point-of care laboratory, as it was initially
anticipated.
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